The latest update is out from Perspective Therapeutics ( (CATX) ).
Neuroendocrine tumors (NETs) are a type of cancerous growth affecting cells that send hormones around the body. Pancreatic neuroendocrine tumors (PNETs) grow in the cells of the pancreas that produce ...
Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...
Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo. The Food and Drug Administration (FDA) has approved Cabometyx ® (cabozantinib) for ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and older ...
The field of oncology has seen significant advancements in understanding and treating various types of cancers. One such area ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback